Navigation Links
Tablet is better all round for cancer patients
Date:10/8/2007

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

Standard chemotherapy can be incredibly disruptive to peoples lives, said Prof Professor Chris Twelves of the University of Leeds, who led the research. Patients visit hospital five days a week for the injections and then have three weeks off before returning to hospital for the next course and the side effects can be unpleasant.

The oral chemotherapy drug Xeloda (capecitabine) offers fewer side-effects and less time in hospital and the trial has shown that patients given the drug were at least as likely to be alive and free of their disease as those on standard chemotherapy (the Mayo Clinic regimen).

The research showed that about 71 percent of patients given Xeloda were still alive after five years, compared to 68 percent of patients treated with standard chemotherapy injections.

Prof Twelvess study followed 1,987 patients who had undergone colon cancer surgery. It found that patients treated with Xeloda spent 85 percent less time with their doctor or at the hospital, and experienced fewer side effects. The new results, showing patients five-year survival rates, confirm the effectiveness of the treatment.

We now have long-term evidence now that clearly supports Xeloda's superiority over the Mayo Clinic regimen, said Prof Twelves. There is now no reason why we should ask colon cancer patients to endure the burdens associated with that older treatment.


'/>"/>
Contact: Simon Jenkins
J.Hicks@leeds.ac.uk
0044-011-334-34031
University of Leeds
Source:Eurekalert

Page: 1

Related medicine news :

1. Clarithromycin tablets to be launched in India soon
2. Cadila gets US FDA approval for Promethazine tablets
3. Say no to detox tablets
4. Manic Ecstasy: Man gets Into a Frenzy after a Record Consumption of 40,000 ecstasy tablets
5. Three Arrested For Illegal Export Of Ephedrine Tablets
6. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
7. Cadila Gets Tentative USFDA Nod For Pravastatin Sodium Tablets
8. Lupin Gets USFDA Approval For Quinapril Tablets
9. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
10. Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets
11. Ranbaxy Launches Clarithromycin, Terbinafine Tablets in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... announced today the addition of an affiliate in Minneapolis-St. Paul, MN, Dr. Adam ... accelerated detox, Naltrexone therapy and aftercare planning through his Timewise Medical practice in ...
(Date:9/25/2017)... ... 2017 , ... SyncDog, Inc., the leading ISV ... will be available in a managed cloud services model, available from its new ... new enhancements including support for caller ID and network sharing for remote users, ...
(Date:9/25/2017)... Church, VA (PRWEB) , ... September 25, 2017 ... ... & Trump, **An FDAnews Webinar**, Oct. 12, 2017 — 1:30 p.m. – 3:00 ... off to a running start. Just look what’s happened in four short months:, ...
(Date:9/25/2017)... ... September 25, 2017 , ... The award is named in honor of Betty ... year the award is given to those who exemplify the mission of Community Options ... in communities of their choosing. Recent recipients of this award include Governor Tom Kean, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Just ask anyone old enough ... or 1980s, with headgear so wired up and containing so much metal that jokes ... so discreet that its treatments can barely be observed. As a result, it’s now ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
Breaking Medicine Technology: